In his weekly clinical update, Dr. Griffin discusses immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age, influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults, COVID-19 surveillance after expiration of the public health emergency declaration, provisional mortality data, targeted vaccine messaging to promote COVID-19 vaccines for children and youth, vaccines and related biological products advisory committee meeting June 15, 2023 announcement, how to overhaul the CDC, impact of SARS-CoV-2 variants on inpatient clinical outcome, prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status, gut bacteria cocktail helps long COVID, and gut microbiota‐derived symbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Immunogenicity and tolerability of a bivalent norovirus vaccine in children (HVI)
• Influenza hemagglutinin stem nanoparticle vaccine induces neutralizing antibodies in healthy adults (STM)
• COVID-19 surveillance after expiration of the public health emergency declaration (CDC)
• Provisional mortality data (CDC)
• Targeted messaging to promote COVID-19 vaccines for children and youth (Pediatrics)
• Vaccines and biological products advisory committee meeting announcement (FDA)
• How to overhaul the C.D.C (NYTIMES)
• Impact of SARS-CoV-2 variants on inpatient clinical outcome (CID)
• Prevalence of post-COVID19 condition 12 weeks after Omicron infection and vaccination status (CID)
• Gut bacteria cocktail helps long COVID (MedPage)
• Gut microbiota‐derived synbiotic formula as a therapy for COVID‐19 (NIH)
• Contribute to our FIMRC fundraiser at PWB
• Letters read on TWiV 1006
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]